콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

S-008

Supelco

Sufentanil Citrate solution

100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C22H30N2O2S · C6H8O7
CAS Number:
60561-17-3
Molecular Weight:
578.67
EC Number:
200-659-6
MDL number:
MFCD00072116
UNSPSC 코드:
41116107
PubChem Substance ID:
329824410
NACRES:
NA.24

Grade

certified reference material

형태

liquid

특징

Snap-N-Spike®/Snap-N-Shoot®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

농도

100 μg/mL in methanol (as free base)

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

forensics and toxicology

형식

single component solution

저장 온도

-10 to -25°C

SMILES string

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCC(=O)N(c1ccccc1)C2(CCN(CCc3cccs3)CC2)COC

InChI

1S/C22H30N2O2S.C6H8O7/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,17H,3,11-16,18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

InChI key

OJCZPLDERGDQRJ-UHFFFAOYSA-N

유전자 정보

human ... OPRM1(4988)

관련 카테고리

일반 설명

Sufentanil is a short acting synthetic opioid analgesic most commonly used for pain relief during medical operations. This certified solution standard is applicable to use in clinical toxicology, pain prescription monitoring, or forensic analysis by LC-MS/MS or GC/MS. Sufentanil is sold under the trade name Sufenta.

법적 정보

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

관련 제품

제품 번호
설명
가격

A-071

Alfentanil hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

F-001

Fentanyl-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-002

Fentanyl solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-013

Fentanyl solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-030

Norfentanyl-D5 oxalate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-031

Norfentanyl oxalate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-055

Norfentanyl-D5 oxalate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

S-018

Sufentanil-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-066

Butyryl fentanyl solution, 100 μg/mL in methanol, certified reference material, ampule of 0.5 mL, Cerilliant®

C-162

Carfentanil Oxalate solution, (sold as 100 ug/mL in methanol as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

C-163

Carfentanil-D5 Oxalate solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

M-194

(±)-cis-3-Methylfentanyl hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

A-139

4-ANPP solution, 100 μg/mL in methanol, certified reference material, ampule of 0.5 mL, Cerilliant®

F-049

p-Fluorofentanyl solution, 100 μg/mL in methanol, certified reference material, ampule of 0.5 mL, Cerilliant®

I-038

Isobutyryl fentanyl hydrochloride solution, 100 μg/mL in methanol (as a free base), certified reference material, ampule of 0.5 mL, Cerilliant®

N-114

Norcarfentanil oxalate oxalate salt solution, 100 μg/mL in methanol (as a free base), certified reference material, ampule of 0.5 mL, Cerilliant®

V-048

Valeryl fentanyl hydrochloride solution, 100 μg/mL in methanol (as a free base), certified reference material, ampule of 0.5 mL, Cerilliant®

A-140

Acryl fentanyl hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

O-047

Ocfentanil solution, 100 μg/mL in methanol, certified reference material, ampule of 0.5 mL, Cerilliant®

F-048

p-Fluorobutyryl fentanyl (PFBF) solution, 100 μg/mL in methanol (), certified reference material, ampule of 0.5 mL, Cerilliant®

H-130

(±)-β-Hydroxythiofentanyl hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

D-168

N-Desmethyl U-47700-D3 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

D-167

N-Desmethyl U-47700 solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

F-050

4-Fluoro-isobutyryl fentanyl solution, 100 μg/mL in methanol, certified reference material, ampule of 0.5 mL, Cerilliant®

A-157

4-ANPP-D5 solution, 100 μg/mL in methanol, certified reference material, ampule of 0.5 mL, Cerilliant®

F-054

o-Fluorofentanyl hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

M-200

Methoxyacetyl fentanyl hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

V-068

Valeryl fentanyl-D5 hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

C-177

Cyclopropyl fentanyl hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

F-053

Furanyl fentanyl-D5 hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

A-156

Acryl fentanyl-D5 hydrochloride solution, 100 μg/mL in methanol (as free base), certified reference material, ampule of 0.5 mL, Cerilliant®

픽토그램

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

신호어

Danger

유해 및 위험 성명서

H225,H301 + H311 + H331,H370

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

표적 기관

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point (°F)

49.5 °F - closed cup

Flash Point (°C)

9.7 °C - closed cup

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Robert Stephen et al.
Journal of opioid management, 8(4), 237-241 (2012-09-04)
In emergency medicine, the ability to provide rapid, adequate pain control without high resource utilization is ideal. In this study, the efficacy of intranasal sufentanil in emergency department (ED) patients with acute distal extremity injury was evaluated. A nonrandomized, open-label
J Fechner et al.
European journal of pain (London, England), 17(4), 562-570 (2012-08-29)
There is an ongoing debate whether opioids when used for intra-operative analgesia may enhance post-operative pain. We studied the effect of two different intra-operative dosings of sufentanil on post-operative morphine consumption, pain and hyperalgesia after cardiac anaesthesia. Forty-two male patients
Marc Lilot et al.
Anesthesia and analgesia, 117(1), 259-264 (2013-04-18)
In this randomized, prospective trial, we sought to determine the effective dose of hypobaric ropivacaine with sufentanil providing 95% success (ED95) in spinal anesthesia for traumatic femoral neck surgery in the elderly. Sixty-eight elderly patients with unilateral hip fracture randomly
Xin Wang et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 21(5), 1140-1145 (2012-12-12)
To evaluate the effect of combined local anaesthetic and opioid in post-operative analgesia, the effect of intra-articular injection of local anaesthetic (ropivacaine), opioid (sufentanil) and combination of these two (ropivacaine combined with sufentanil) after the single-bundle anterior cruciate ligament reconstruction
S Karason et al.
Acta anaesthesiologica Scandinavica, 57(5), 639-645 (2013-02-26)
Bladder catheterisation may be inconvenient for patients, delay mobilisation and risk complications. We hypothesised that by excluding pre-operatively patients at high risk of post-operative urinary retention, the majority of patients could avoid perioperative catheterisation during low-dose spinal anaesthesia. Patients undergoing
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.